Analytical Data
-
Gene name
Mamu-A*01 B2M Monomer
- Application
-
Alternative Names
Mamu-A*01 & B2M
-
Species
Rhesus Macaque
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5TM76 (G25-P307)&Q6V7J5
-
Expression Region
Q5TM76 (G25-P307)&Q6V7J5 (I21-M119)
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Mamu-A*01 B2M monomer is a recombinant protein derived from the rhesus macaque, a primate model that plays a crucial role in immunological studies, particularly in understanding human diseases and vaccine responses. Mamu-A*01 is a major histocompatibility complex (MHC) class I molecule that presents antigens to CD8+ T cells, influencing immune responses during infections and cancer. The study of this protein is vital as it provides insights into T cell recognition and responses, which can differ significantly from those in humans. With the increasing interest in cross-species T cell studies and the development of effective therapeutic strategies, researchers have focused on characterizing Mamu-A*01 B2M monomer to elucidate its structural and functional properties. The development of recombinant forms of this protein allows for better functional assays and improves the understanding of its role in the immune landscape of primates. Moreover, studying this protein can aid in vaccine development processes and enhance our knowledge of viral immunology, given the similarities between non-human primates and humans in immune system responses. Overall, the research surrounding Mamu-A*01 B2M monomer embodies a significant step toward translating findings from non-human primate models into potential clinical applications and improved therapeutic interventions for human diseases.
